PL2448970T3 - Przeciwciało przeciwko czynnikowi wzrostu nerwów (NGF) ze zwiększoną stabilnością in vivo - Google Patents

Przeciwciało przeciwko czynnikowi wzrostu nerwów (NGF) ze zwiększoną stabilnością in vivo

Info

Publication number
PL2448970T3
PL2448970T3 PL10730827T PL10730827T PL2448970T3 PL 2448970 T3 PL2448970 T3 PL 2448970T3 PL 10730827 T PL10730827 T PL 10730827T PL 10730827 T PL10730827 T PL 10730827T PL 2448970 T3 PL2448970 T3 PL 2448970T3
Authority
PL
Poland
Prior art keywords
ngf
enhanced
growth factor
antibodies against
nerve growth
Prior art date
Application number
PL10730827T
Other languages
English (en)
Inventor
John Powell
Mark Maginn
Duncan Casson
Andrea Best
Jerry A Hall
Wei Liu
Sandeep Dutta
Original Assignee
Abbvie Res B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Res B V filed Critical Abbvie Res B V
Publication of PL2448970T3 publication Critical patent/PL2448970T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10730827T 2009-05-04 2010-05-04 Przeciwciało przeciwko czynnikowi wzrostu nerwów (NGF) ze zwiększoną stabilnością in vivo PL2448970T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17522809P 2009-05-04 2009-05-04
US22725109P 2009-07-21 2009-07-21
US23881309P 2009-09-01 2009-09-01
US25231409P 2009-10-16 2009-10-16
EP10730827.2A EP2448970B1 (en) 2009-05-04 2010-05-04 Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
PCT/IB2010/001210 WO2010128398A1 (en) 2009-05-04 2010-05-04 Antibodies against nerve growth factor (ngf) with enhanced in vivo stability

Publications (1)

Publication Number Publication Date
PL2448970T3 true PL2448970T3 (pl) 2014-12-31

Family

ID=43030513

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10730827T PL2448970T3 (pl) 2009-05-04 2010-05-04 Przeciwciało przeciwko czynnikowi wzrostu nerwów (NGF) ze zwiększoną stabilnością in vivo

Country Status (31)

Country Link
US (2) US8435523B2 (pl)
EP (1) EP2448970B1 (pl)
JP (2) JP5898064B2 (pl)
KR (1) KR20120088550A (pl)
CN (1) CN102459337B (pl)
AR (1) AR076650A1 (pl)
AU (1) AU2010244133B2 (pl)
BR (1) BRPI1014445A8 (pl)
CA (1) CA2761203A1 (pl)
CL (1) CL2011002765A1 (pl)
CO (1) CO6470819A2 (pl)
CR (1) CR20110629A (pl)
DK (1) DK2448970T3 (pl)
DO (1) DOP2011000337A (pl)
EC (1) ECSP11011502A (pl)
ES (1) ES2514319T3 (pl)
HK (1) HK1170508A1 (pl)
HR (1) HRP20140915T1 (pl)
IL (1) IL216128A (pl)
MX (1) MX2011011728A (pl)
NZ (1) NZ596839A (pl)
PE (1) PE20121540A1 (pl)
PL (1) PL2448970T3 (pl)
PT (1) PT2448970E (pl)
RU (1) RU2549679C2 (pl)
SG (1) SG175436A1 (pl)
SI (1) SI2448970T1 (pl)
TW (1) TWI486171B (pl)
UA (1) UA104890C2 (pl)
UY (1) UY32608A (pl)
WO (1) WO2010128398A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
KR101250818B1 (ko) 2002-12-24 2013-04-15 리나트 뉴로사이언스 코프. 항-ｎｇｆ 항체 및 그것을 이용하는 방법
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
MX2010001395A (es) 2007-08-10 2010-03-10 Regeneron Pharma Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
SG183983A1 (en) 2010-03-17 2012-10-30 Abbott Res Bv Anti-nerve growth factor (ngf) antibody compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
PT2654790T (pt) * 2010-12-22 2019-05-16 Teva Pharmaceuticals Australia Pty Ltd Anticorpo modificado com semivida melhorada
JP6181043B2 (ja) 2011-05-06 2017-08-16 ネックスヴェット オーストラリア プロプライエタリー リミテッド 抗神経成長因子抗体ならびにそれを調製および使用する方法
ME02944B (me) 2011-08-11 2018-04-20 Astellas Pharma Inc Novo antitelo protiv humanog ngf
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
GB201412748D0 (en) * 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
KR200480634Y1 (ko) 2015-04-14 2016-06-16 한전케이피에스 주식회사 긴급복구용 윈치의 고정장치
US11260124B2 (en) 2015-05-22 2022-03-01 Astellas Pharma Inc. Anti-human NGF antibody Fab fragment and methods for treating postoperative pain related to NGF
IT201700066486A1 (it) * 2017-06-15 2018-12-15 Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologn A Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche
CN108623687A (zh) 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用
EP3795176A4 (en) 2018-05-15 2022-01-12 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF ATRIAL FIBRILLATION WITH ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AS AN ACTIVE SUBSTANCE
GB2579707A (en) 2018-10-15 2020-07-01 Avent Inc Compositions, systems, kits, and methods for neural ablation
WO2020248942A1 (zh) * 2019-06-10 2020-12-17 山东博安生物技术有限公司 抗β-NGF纳米抗体及其应用
CN110583625A (zh) * 2019-09-17 2019-12-20 深圳大学 一种脐带储存液
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Ampsource Biopharma Shanghai Inc. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
CN116178541A (zh) * 2020-08-06 2023-05-30 熙源安健医药（上海）有限公司 抗ngf抗体及其抗原结合片段、其制备方法和应用
EP4230732A1 (en) 2021-07-30 2023-08-23 Chengdu Unovel Biopharma Co., Ltd. Recombinant cho cell, construction method therefor, and detection system and method using same

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230691A (en) 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
SE465573B (sv) 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1992009631A1 (en) 1990-11-30 1992-06-11 Abbott Laboratories Immunoassay and monoclonal antibodies useful for detecting truncated nerve growth factor receptor
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
EP0578515A3 (en) 1992-05-26 1995-05-10 Bristol Myers Squibb Co Humanized monoclonal antibodies.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
ATE463567T1 (de) 1999-08-06 2010-04-15 S I S S A Scuola Internaz Supe Transgene mäuse zur studierung von neurodegenerativen syndromen
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
DK1401498T3 (da) 2001-05-30 2011-11-21 Genentech Inc Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
WO2004032852A2 (en) 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
DE60335957D1 (de) 2002-10-08 2011-03-17 Rinat Neuroscience Corp Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
AU2003286467B2 (en) * 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1891966T3 (da) 2002-12-20 2012-04-02 Lundbeck & Co As H Modulation af neurotrophinaktivitet; fremgangsmåde til screening
KR101250818B1 (ko) 2002-12-24 2013-04-15 리나트 뉴로사이언스 코프. 항-ｎｇｆ 항체 및 그것을 이용하는 방법
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US20060147932A1 (en) 2003-01-18 2006-07-06 Alun Davies Methods of screening for modulators of nerve growth factor
US7655231B2 (en) 2003-02-19 2010-02-02 Pfizer Inc. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID
CN1871028A (zh) * 2003-02-19 2006-11-29 里纳特神经***学公司 通过施用神经生长因子拮抗剂和nsaid和含有它们的组合物治疗疼痛的方法
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
MEP31508A (en) 2003-07-15 2010-10-10 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
EP1682170A2 (en) 2003-11-07 2006-07-26 Lay Line Genomics SpA Compositions able to prevent neurodegenerative processes and methods of assaying the same
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
NZ549990A (en) 2004-04-07 2009-08-28 Rinat Neuroscience Copr Methods for treating bone cancer pain by administering a nerve growth factor antagonist
ITRM20040212A1 (it) 2004-04-30 2004-07-30 Lay Line Genomics Spa Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce.
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
ES2387312T3 (es) 2004-09-22 2012-09-20 Kyowa Hakko Kirin Co., Ltd. Anticuerpos IgG4 humanos estabilizados
US7589179B2 (en) * 2004-12-09 2009-09-15 Merck Patent Gmbh IL-7 variants with reduced immunogenicity
US9315571B2 (en) 2005-01-24 2016-04-19 Elan Pharma International Limited Specific binding members for NGF
EP1915394B1 (en) 2005-05-20 2021-01-27 Lonza Biologics plc. High-level expression of recombinant antibody in a mammalian host cell
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
US20080213282A1 (en) 2006-12-21 2008-09-04 Jaby Jacob Formulations
CA2688275A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
MX2010001395A (es) 2007-08-10 2010-03-10 Regeneron Pharma Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
KR20130087632A (ko) 2007-12-17 2013-08-06 화이자 리미티드 간질성 방광염의 치료
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
US8435523B2 (en) * 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
WO2011000020A1 (en) 2009-06-12 2011-01-06 Sbc Research Pty Ltd Enhanced method of detection
SG183983A1 (en) 2010-03-17 2012-10-30 Abbott Res Bv Anti-nerve growth factor (ngf) antibody compositions

Also Published As

Publication number Publication date
CR20110629A (es) 2012-05-28
JP2016026221A (ja) 2016-02-12
WO2010128398A1 (en) 2010-11-11
DK2448970T3 (da) 2014-10-06
RU2011149263A (ru) 2013-06-10
BRPI1014445A8 (pt) 2018-01-09
AU2010244133B2 (en) 2015-07-23
IL216128A (en) 2015-10-29
EP2448970A1 (en) 2012-05-09
JP5898064B2 (ja) 2016-04-06
EP2448970B1 (en) 2014-07-09
HK1170508A1 (en) 2013-03-01
TW201043246A (en) 2010-12-16
ECSP11011502A (es) 2012-04-30
DOP2011000337A (es) 2012-02-15
ES2514319T3 (es) 2014-10-28
UA104890C2 (uk) 2014-03-25
CL2011002765A1 (es) 2012-07-20
PE20121540A1 (es) 2012-12-22
US20100278839A1 (en) 2010-11-04
KR20120088550A (ko) 2012-08-08
CN102459337A (zh) 2012-05-16
JP2012525838A (ja) 2012-10-25
UY32608A (es) 2010-12-31
AR076650A1 (es) 2011-06-29
CO6470819A2 (es) 2012-06-29
RU2549679C2 (ru) 2015-04-27
BRPI1014445A2 (pt) 2016-11-29
US9447181B2 (en) 2016-09-20
US20130295112A1 (en) 2013-11-07
HRP20140915T1 (hr) 2014-12-05
AU2010244133A1 (en) 2011-12-15
CN102459337B (zh) 2015-05-20
PT2448970E (pt) 2014-10-20
NZ596839A (en) 2014-01-31
SG175436A1 (en) 2011-12-29
IL216128A0 (en) 2012-01-31
CA2761203A1 (en) 2010-11-11
US8435523B2 (en) 2013-05-07
TWI486171B (zh) 2015-06-01
MX2011011728A (es) 2012-04-19
SI2448970T1 (sl) 2014-11-28

Similar Documents

Publication Publication Date Title
HK1170508A1 (en) Antibodies against nerve growth factor (ngf) with enhanced in vivo stability (ngf)
ZA201207249B (en) Human anti-il-6 antibodies with extended in vivo half-life
EP2463371A4 (en) CONJUGATE AND METHOD FOR PREPARING SIRNA
IL218022A0 (en) Corneal inlay with nutrient transport structures
ZA201200333B (en) Artificial airway
HK1167666A1 (en) Anti-fgfr3 antibodies and methods using same -fgfr3
EP2237741A4 (en) ENDOLUMINAL FILTER WITH FIXATION
HK1161275A1 (en) Halogen-stabilized insulin
EP2479320A4 (en) FIBER AND FIBER STRUCTURE
ZA201007773B (en) Prosthesis with composite component
EP2407539A4 (en) MULTIMERISED ARNSI AND PREPARATION METHOD THEREOF
EP2414535A4 (en) BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS OF USE
EP2334209A4 (en) FILE HAVING HAND FASTENING HAIR Weaving
ZA201107187B (en) Daatabase schema complexity reduction
HK1161720A1 (en) Dihydroetorphines and their preparation
GB0816577D0 (en) Growth factor
GB2459082B (en) Improvements in artificial lift mechanisms
ZA201007770B (en) Prosthesis with modular extentions
EG26793A (en) Medical Injector
GB201013301D0 (en) Improvements in artificial lift mechanisms
HU0900178D0 (en) Stronger paper-pallet with use of simple geometrical structure
GB0912032D0 (en) Porous growing mat with nutritional properties
GB2457811B (en) Container with alignment means
PL393280A1 (pl) Wódka gatunkowa gorzka z dodatkiem naturalnych substancji goryczkowych
GB0810924D0 (en) In vivo transgenics